Copyright
©The Author(s) 2022.
World J Gastroenterol. Jun 28, 2022; 28(24): 2689-2704
Published online Jun 28, 2022. doi: 10.3748/wjg.v28.i24.2689
Published online Jun 28, 2022. doi: 10.3748/wjg.v28.i24.2689
Figure 1 The efficiency of TNFR1 and TNFR2 expression silencing in AGS cells.
A and B: Expression levels of TNFR1 and TNFR2 mRNA evaluated by real-time reverse transcription-quantitative polymerase chain reaction; C and D: Protein expression of TNFR1 and TNFR2 evaluated by Western blotting. Downregulation of TNFR1 (A-C) and TNFR2 (B-D) was confirmed by the reduction in the expression of receptors TNFR1 and TNFR2 following treatment with shRNAs 2 and 4, respectively. AGS: Nonsilenced cell line; C: Control transfected with empty vector; 1 and 2: Different shRNA clones for TNFR1; 3 and 4: Different shRNA clones for TNFR2.
- Citation: Rossi AFT, da Silva Manoel-Caetano F, Biselli JM, Cabral ÁS, Saiki MFC, Ribeiro ML, Silva AE. Downregulation of TNFR2 decreases survival gene expression, promotes apoptosis and affects the cell cycle of gastric cancer cells. World J Gastroenterol 2022; 28(24): 2689-2704
- URL: https://www.wjgnet.com/1007-9327/full/v28/i24/2689.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i24.2689